Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroksaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotična sredstva - preprečevanje venska trombembolija (vte) pri odraslih bolnikih, ki so v postopku izbirni kirurški zamenjavi kolka ali kolena. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. (see section 4. 4 for haemodynamically unstable pe patients. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. (see section 4. 4 za haemodynamically nestabilno pe bolnikov). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 in 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Evropska unija - slovenščina - EMA (European Medicines Agency)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotična sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

acetilsalicilna kislina; rosuvastatin - kapsula, trda - acetilsalicilna kislina 100 mg / 1 kapsula  rosuvastatin10 mg / 1 kapsula; rosuvastatin 10 mg / 1 kapsula - rosuvastatin in acetilsalicilna kislina

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

acetilsalicilna kislina; rosuvastatin - kapsula, trda - acetilsalicilna kislina 100 mg / 1 kapsula  rosuvastatin20 mg / 1 kapsula; rosuvastatin 20 mg / 1 kapsula - rosuvastatin in acetilsalicilna kislina

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

acetilsalicilna kislina; rosuvastatin - kapsula, trda - acetilsalicilna kislina 100 mg / 1 kapsula  rosuvastatin5 mg / 1 kapsula; rosuvastatin 5 mg / 1 kapsula - rosuvastatin in acetilsalicilna kislina

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

alkaloid - int d.o.o. - klopidogrel - filmsko obložena tableta - klopidogrel 75 mg / 1 tableta - klopidogrel

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

stada arzneimittel ag - duloksetin - gastrorezistentna kapsula, trda - duloksetin 30 mg / 1 kapsula - duloksetin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

stada arzneimittel ag - duloksetin - gastrorezistentna kapsula, trda - duloksetin 60 mg / 1 kapsula - duloksetin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer luxembourg sarl - klopidogrel - filmsko obložena tableta - klopidogrel 75 mg / 1 tableta - klopidogrel

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

splendris pharmaceuticals gmbh - klopidogrel - filmsko obložena tableta - klopidogrel 75 mg / 1 tableta - klopidogrel